secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001558370-25-011778
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Animal Health Q4 net sales up 39% to $378.7M; FY2026 guidance sees 25% adj. EBITDA growth
--------------------------------------------------------------------------------

- Q4 net sales $378.7M (+39% YoY), net income $17.2M vs $0.8M, adj. diluted EPS $0.57 (+39%).
- FY net sales $1,296.2M (+27%), adj. EBITDA $183.7M (+65%), adj. diluted EPS $2.09 (+76%).
- Zoetis MFA portfolio contributed $94.5M incremental revenue in Q4 and $208.2M for full year.
- FY2026 guidance: net sales $1.43-1.48B, adj. EBITDA $225-235M (25% growth), adj. EPS $2.52-2.70.
- Gross leverage 3.1x as of June 30, 2025; free cash flow $41.8M for the year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837025011778/0001558370-25-011778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837025011778/pahc-20250827x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer